Inmode Ltd Stock Fair Value Calculation – InMode Ltd. Shares Gain Despite Underwhelming Earnings Guidance as Q4 2022 Results Exceed Forecasts.

Trending News ☀️

Inmode Ltd Stock Fair Value Calculation – INMODE ($NASDAQ:INMD): InMode Ltd., an Israeli MedTech company that specializes in non-invasive, minimally invasive and laser-assisted cosmetic procedures, recently saw its stock prices surge despite offering underwhelming guidance for its earnings. Over the course of the last year, InMode’s stock prices have remained relatively stable, despite the pandemic-driven economic downturn, partially due to its strong presence in the cosmetic surgery market. InMode has continued to expand its offerings over the past few years, most recently launching its “Lumecca” products for skin rejuvenation, which were well received by its customers. The company has also made recent strides in expanding into new markets around the globe, with plans to launch its products in China later this year.

Additionally, InMode is looking to expand its presence in Europe and Latin America and is actively seeking partnerships with medical device companies in these regions in order to further fuel its growth. Overall, InMode Ltd. has been able to weather the storm of the economic downturn and continues to perform well, as evidenced by its impressive fourth quarter earnings. With plans to continue expanding its product offerings and presence around the world, investors seem bullish on the future of InMode Ltd.

Price History

INMODE LTD has had largely positive media coverage since Tuesday when the company’s stock opened at $34.0 and closed at $37.6, an increase of 10.5% from the prior closing price of 34.0. These results showed consistent growth in the company’s overall financial performance and were bolstered by strong performances in its core businesses. The positive news sent INMODE LTD’s shares soaring as investors responded favorably to the better-than-expected results. Despite this, INMODE LTD has continued to deliver impressive results and reward investors with a 10.5% surge in stock price on Tuesday.

This positive sentiment is expected to continue in the near future as investors remain optimistic on the company’s long-term prospects. As such, INMODE LTD is likely to remain a strong performer in the stock market for some time to come. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Inmode Ltd. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Inmode Ltd. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Inmode Ltd. More…

Key Ratios Snapshot

Some of the financial key ratios for Inmode Ltd are shown below. More…

Analysis – Inmode Ltd Stock Fair Value Calculation

GoodWhale’s analysis of its fundamentals reveals that the fair value of its stock is around $45.6, calculated using our proprietary Valuation Line. Currently, the stock is trading at $37.6, so it is undervalued by 17.5%. This is an ideal opportunity for investors to purchase a stock at a below-market price and potentially benefit from the upside. INMODE LTD has established a strong presence in the healthcare and technology markets, with their products used in a variety of medical procedures. Their innovative products have allowed them to become a leader in the field and drive revenue growth. Their financials are stable and their balance sheet is strong, making it an attractive option for investors. Additionally, their management team is highly experienced and has demonstrated an ability to lead the company to success. Overall, INMODE LTD is an interesting opportunity for investors and traders. With its currently undervalued stock price and strong fundamentals, this could be a great chance to capitalize on potential upside. Investors should be sure to assess the company’s fundamentals and risk profile before making any decisions and seek professional investment advice if necessary. More…

Peers

The market for aesthetic medical device is highly competitive with InMode Ltd. facing competition from Cutera Inc., Viveve Medical Inc., and Apyx Medical Corp. All four companies offer a range of products that target different areas of the body and address different aesthetic concerns. InMode Ltd. has a strong portfolio of products that are backed by clinical data and have a proven track record of safety and efficacy. The company’s products are also available in a variety of price points to meet the needs of different consumers.

– Cutera Inc ($NASDAQ:CUTR)

Cutera Inc is a medical device company that provides aesthetic treatments to patients worldwide. Founded in 1998, Cutera is headquartered in Brisbane, California, and has a market cap of 931.59M as of 2022. The company’s Return on Equity is -111.73%. Cutera’s products are used by physicians and other healthcare professionals to treat conditions such as wrinkles, acne, vascular lesions, and unwanted hair. The company’s products include laser and light-based devices, intense pulsed light devices, and radiofrequency devices.

– Viveve Medical Inc ($NASDAQ:VIVE)

Viveve Medical Inc. is a medical technology company that focuses on the treatment of female intimate health conditions. The company’s flagship product is the Viveve System, which is used to treat vaginal laxity, the condition where the vaginal walls become stretched and loose. The Viveve System uses radiofrequency energy to heat tissue and stimulate collagen production, which results in tighter, healthier tissue.

Viveve Medical Inc has a market cap of 6.19M as of 2022. The company’s Return on Equity is -179.17%. The company’s flagship product is the Viveve System, which is used to treat vaginal laxity. The Viveve System uses radiofrequency energy to heat tissue and stimulate collagen production, which results in tighter, healthier tissue.

– Apyx Medical Corp ($NASDAQ:APYX)

Apyx Medical Corp is a medical device company that develops, manufactures, and markets radiofrequency (RF) products for the global surgical market. The company’s products include the Renuvion System, a minimally invasive RF technology for tissue remodeling and tightening, and the J-Plasma System, a next-generation plasma-based technology.

Apyx Medical Corp has a market cap of 149.01M as of 2022, a Return on Equity of -22.62%. The company develops, manufactures, and markets radiofrequency (RF) products for the global surgical market. The company’s products include the Renuvion System, a minimally invasive RF technology for tissue remodeling and tightening, and the J-Plasma System, a next-generation plasma-based technology.

Summary

Despite providing underwhelming earnings guidance, the company’s quarterly results exceeded expectations, causing its stock to rise the same day. The strong performance has been met with mostly positive media coverage thus far. Investors should further research the company’s performance, customer sentiment, and future growth plans before making any decision to invest in InMode Ltd.